Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Baxter
Express Scripts
McKesson

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OMACETAXINE MEPESUCCINATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Omacetaxine Mepesuccinate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002574 ↗ Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1994-09-01 Phase II trial to study the effectiveness of homoharringtonine and interferon alfa in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Combining chemotherapy with interferon alfa may kill more cancer cells.
NCT00003239 ↗ Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003239 ↗ Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed M.D. Anderson Cancer Center Phase 2 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with cytarabine and homoharringtonine and biological therapy with interferon alfa in treating patients with chronic phase chronic myelogenous leukemia.
NCT00003694 ↗ Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Completed National Cancer Institute (NCI) Phase 2 1999-03-01 Phase II trial to study the effectiveness of homoharringtonine plus low-dose cytarabine in treating patients who have newly diagnosed chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
NCT00006364 ↗ Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1999-11-01 Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Omacetaxine Mepesuccinate

Condition Name

Condition Name for Omacetaxine Mepesuccinate
Intervention Trials
Chronic Myeloid Leukemia 3
AML 2
Leukemia 2
Chronic Myelogenous Leukemia, BCR-ABL1 Positive 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Omacetaxine Mepesuccinate
Intervention Trials
Leukemia 10
Leukemia, Myeloid 10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8
Leukemia, Myeloid, Chronic-Phase 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Omacetaxine Mepesuccinate

Trials by Country

Trials by Country for Omacetaxine Mepesuccinate
Location Trials
United States 33
France 3
Hungary 2
Poland 2
Hong Kong 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Omacetaxine Mepesuccinate
Location Trials
Texas 9
New York 4
Indiana 3
Massachusetts 3
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Omacetaxine Mepesuccinate

Clinical Trial Phase

Clinical Trial Phase for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Phase 2 10
Phase 1/Phase 2 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Omacetaxine Mepesuccinate
Clinical Trial Phase Trials
Completed 9
Terminated 4
Recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Omacetaxine Mepesuccinate

Sponsor Name

Sponsor Name for Omacetaxine Mepesuccinate
Sponsor Trials
National Cancer Institute (NCI) 5
ChemGenex Pharmaceuticals 4
Teva Branded Pharmaceutical Products R&D, Inc. 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Omacetaxine Mepesuccinate
Sponsor Trials
Industry 16
Other 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
Harvard Business School
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.